Fuzeon

This page contains recent news articles, when available, and an overview of Fuzeon but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Fuzeon (when available)

Pharmacology and use:
Not Available For treatment of HIV AIDS

Mechanism Of Action:
Not Available

News Articles on Enfuvirtide

Raltegravir may cause temporary worsening of pre-existing depression  -  Sep 2, 2008
There were two reasons why the patients started treatment with raltegravir: switch from T-20 (enfuvirtide, Fuzeon) or gastrointestinal problems caused by a Aidsmap,

Analyst Blog Trimeris Has Further to Fall  -  Aug 19, 2008
US sales of Fuzeon came in at only $16.1 million in the second quarter of 2008, down 51 percent year-over-year. Ex-US sales of Fuzeon were $22.2 million, Zacks.com,

New Zealand HIV Patients Given Hope  -  Sep 4, 2008
...living with HIV as we haven't had a new class of medication since the introduction of FUZEON, which has to be injected rather than taken as a tablet. Scoop.co.nz (press release),

Zacks Sell List Highlights: Washington Mutual Inc, Lear Corp ...  -  Aug 28, 2008
Trimeris Inc.'s (NASDAQ: TRMS) second-quarter profit fell 87%, largely due to waning sales of its AIDS drug Fuzeon and a large restructuring charge. PR-Inside.com (Pressemitteilung),

Inalcanzables las medicinas de patente  -  Sep 1, 2008
Los medicamentos que existen en el mercado para el Sida, son: fuzeon, ritonavir, tipranavir, tenofovir, emtricitabina y efaviren2, que le permiten al Diario del Istmo,

Zacks Sell List Highlights: Washington Mutual Inc, Lear Corp ...  -  Aug 28, 2008
Chart | News | PowerRating) second-quarter profit fell 87%, largely due to waning sales of its AIDS drug Fuzeon and a large restructuring charge. Trading Markets (press release),

New HIV treatments slash into sales of Trimeris' Fuzeon  -  Jul 21, 2008
Global sales of Trimeris' HIV drug, Fuzeon, dropped 38 percent in the second quarter, data released Monday say. Trimeris (Nasdaq: TRMS), based in Durham, Bizjournals.com,

Trimeris to Release Second Quarter 2008 Financial Results on ...  -  Aug 2, 2008
FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about FOXBusiness

Roche to suspend HIV research, seeing no advances  -  Jul 11, 2008
Roche said it would continue to support its molecular diagnostic tests and drugs already on the market, including the fusion-inhibitor Fuzeon. Reuters India,

Roche drops HIV drug research programme - report  -  Jul 14, 2008
PK - news - people ) said it will continue to make its Fuzeon, Viracept and Invirase HIV drugs, alongside HIV diagnostics and treatments for conditions Forbes,

Roche abandons HIV research  -  Jul 15, 2008
Another drug, Fuzeon (enfuvirtide) was the first approved drug to prevent HIV fusion with target cells, but it was difficult to use (it had to be injected) Nature.com (subscription),

Roche Halts HIV Treatment Research  -  Jul 15, 2008
The company's other products, Viracept, Fuzeon and Invirase, are known for their similar treatment objectives, with Fuzeon being marketed as a treatment AHN

Roche shifts funding priorities  -  Jul 21, 2008
She added that Roche will continue to support the HIV therapies it already makes, including Fuzeon, a cell fusion inhibitor, which the FDA approved in 2003. Scientist,

Roche Ends HIV Reseach Program  -  Jul 17, 2008
Roche stressed it will continue to manufacture its current HIV drugs, "Fuzeon," "Viracept," and "Invirase," and diagnostics. Peter Staley, founder of Pharmaceutical Technology Magazine,

BUYINS.NET: GLRE, GROW, HOGS, SBKC, STEL, TRMS Have Also Been ...  -  Jul 18, 2008
The company offers FUZEON, a 36-amino acid synthetic peptide that binds to a key region of the human immunodeficiency virus (HIV) surface protein called Trading Markets (press release),

BUYINS.NET: PSEC, SSBX, STAR, SWIR, TDSC, TRMS Have Also Been ...  -  Jul 11, 2008
The company offers FUZEON, a 36-amino acid synthetic peptide that binds to a key region of the human immunodeficiency virus (HIV) surface protein called Trading Markets (press release),

Raltegravir (Isentress) Effective Against Drug-Resistant HIV  -  Jul 23, 2008
...she said, but in many cases may require the use of several different drugs, including the injectable fusion inhibitor enfuvirtide (Fuzeon). MedPage Today,

Company and People Notes: Solvay Pharma Raises Bid for ...  -  Jul 17, 2008
Roche says it will continue making its existing AIDS drugs, “Fuzeon,�? “Viracept,�? and “Invirase,�? and diagnostics. Bothell, WA (July 8)—Seattle Genetics Pharmaceutical Technology Magazine,

Roche halts study of HIV drugs that fight virus two ways  -  Jul 14, 2008
The company said it will continue to manufacture its AIDS drugs -- Fuzeon, Invirase and Viracept -- as well as HIV diagnostics and medications for diseases SmartBrief,

Roche halts study of HIV drugs that fight virus two ways  -  Jul 14, 2008
The company said it will continue to manufacture its AIDS drugs -- Fuzeon, Invirase and Viracept -- as well as HIV diagnostics and medications for diseases SmartBrief,

Roche suspend sa recherche contre le sida  -  Jul 15, 2008
Roche continuera toutefois à commercialiser les médicaments efficaces déjà sur le marché, le Fuzeon, Viracept et Invirase, qui ont enregistré des ventes de Europe1,

Sem avanços, Roche suspende pesquisas sobre Aids  -  Jul 11, 2008
A Roche disse que vai manter no mercado seus exames de diagnóstico molecular e seus medicamentos atuais, como o inibidor de fusão Fuzeon, parceria com a O Globo Online,

Roche suspende su investigación en el área de VIH  -  Jul 18, 2008
...(dos antirretrovirales, saquinavir y nelfinavir, y un inhibidor de la fusión, Fuzeon), se trata de una de las compañías más comprometidas en este área. elmundo.es,

VIH et anguille sous Roche  -  Aug 5, 2008
Mais rassurez-vous, la société continuera tout de même à commercialiser ses produits actuels - Fuzeon, Viracept et Invirase - qui ont enregistré des ventes 24 heures,

El SIDA, un modelo de negocio  -  Jul 28, 2008
...comercializando los productos que ya tenía en el mercado; los antirretrovirales, Saquinavir y Nelfinavir, y un inhibidor de la fusión, Fuzeon. Periodista Digital,

Farmacéutica abandona la investigación del SIDA  -  Jul 22, 2008
No obstante, Roche asegura que seguirá comercializando Invirase, Fuzeon y Viracept, tres de los medicamentos que mejor resultado han dado en los Dminorias,

Roche прекращает разработку препаратов дл�? лечени�? ВИЧ-инфекции  -  Jul 14, 2008
В на�?то�?щее врем�? на рынке при�?ут�?твуют три ее препарата дл�? лечени�? ВИЧ-инфекции: «Fuzeon» (�?нфувиртид), «Viracept» (нелфинавир) и «Invirase» (�?аквинавир). Мед�?ово�?ти,

Recherche sur le VIH : le laboratoire Roche se retire  -  Jul 17, 2008
Les trois médicaments déjà développés par le laboratoire (Invirase, Viracept et Fuzeon) ne représentent qu’une faible part dans le chiffre d’affaires du Web-Libre.org,

Roche termina desenvolvimento de fármacos para o HIV  -  Jul 15, 2008
A Roche adiantou, no entanto, que continuará a apoiar os medicamentos que já tem no mercado, o Fuzeon, Viracept e Invirase. Linda Dyson, porta-voz da Roche Farmacia,

罗�?暂�?�抗艾滋病�?�物研究  -  Jul 14, 2008
...罗�?表示，他们将一如既往地支�?已�?投放市场的抗艾滋病�?�物，其中包括�?�?�抑制剂Fuzeon 中国生物技术信�?�网,

Aids - die ständige Gefahr  -  Aug 1, 2008
Neue Substanzen wurden entwickelt: Mit Enfuvirtide ("Fuzeon") stand ab 2003 ein drittes Therapieprinzip gegen HIV zur Verfügung. Der Wirkstoff hindert die Kleine Zeitung,

Sida: réaction après la décision de Roche  -  Jul 15, 2008
Roche continuera de commercialiser trois médicaments destinés au traitement du VIH/sida - le Fuzeon, Viracept et Invirase - qui ont enregistré des ventes de France 2,

Para os autores, isso mostra a importância do meio nas decisões ...  -  Jul 13, 2008
A Roche disse que vai manter no mercado seus exames de diagnóstico molecular e seus medicamentos atuais, como o inibidor de fusão Fuzeon, parceria com a Agência de Notícias da Aids,

Roche incapable de trouver une meilleure thérapie contre le sida  -  Jul 18, 2008
Le Financial Times a calculé que les trois médicaments développés par Roche - Fuzeon, Viracept et Invirase - ne représentaient que 160 millions de francs Le Temps (Abonnement),

Η φα�?μακοβιομηχανία Roche εγκαταλείπει την έ�?ευνα κατά του HIV  -  Jul 14, 2008
Η Roche θα συνεχίσει πάντως να εμπο�?ε�?εται τα υπά�?χοντα φά�?μακά της κατά του HIV, συμπε�?ιλαμβανομένου του αναστολέα σ�?ντηξης Fuzeon. Ο Φιλελε�?θε�?ος,

SIDA - Treize ans d’espérance de vie en plus  -  Jul 25, 2008
Roche commercialise actuellement trois médicaments destinés au traitement du virus, le Fuzeon, l’Invirase et le Viracept. Ils ne seront pas retirés du France Soir,

Roche Farmacéutica se retira de la investigación en antirretrovirales  -  Jul 16, 2008
Se asegura que Roche seguirá comercializando Invirase, Fuzeon y Viracept. Se da la circunstancia que Viracept estuvo hace poco retirado del mercado unos LaSalud.com.mx,

Roche gibt Aids-Forschung auf  -  Jul 15, 2008
Allerdings hätten die Präparate Fuzeon (Enfuvirtid), Viracept (Nelfinavir) und Invirase (Saquinavir) im vergangenen Jahr „nur“ rund 100 Millionen Euro apotheke-adhoc,

深圳户�?低�?艾滋病患者�?月�?�领救济金  -  Jul 16, 2008
...深圳新闻网讯深圳市�?�生局日�?推出多项关怀艾滋病患者的政策，包括�?�?艾滋病�?�常�?机会性感染的�?�物治疗费用�?深圳户�?低�?艾滋病患者�?月�?�领救济金等。深圳新闻网,

Un homosexuel iranien obtient le statut de réfugié  -  Jul 18, 2008
Le Haut-commissariat des Nations Unies pour les réfugiés (UNHCR) de Turquie a accordé le 15 juillet le statut de réfugié à Kamal, un homosexuel iranien TÊTU,

Government won’t discuss Fuzeon price  -  Jun 25, 2008
The government decided not to discuss the price adjustment of Fuzeon, saying that there is no reason to increase the price of the drug. �?��?�리팜,

BUYINS.NET: NTES, TRMS, CAGC, GMFX, SWVC, ICNJF Have Also Been ...  -  Jun 13, 2008
The company offers FUZEON, a 36-amino acid synthetic peptide that binds to a key region of the human immunodeficiency virus (HIV) surface protein called Trading Markets (press release),

Ardea Takes the More Exciting Route  -  Jun 26, 2008
...lucrative than for developing a compound like Trimeris' (Nasdaq: TRMS) Fuzeon, which is used later on as HIV patients fail to improve with other drugs. Motley Fool

Protein linked to Alzheimer's may spur AIDS  -  Jun 17, 2008
Studies of the proteins have also revealed that they resemble drugs called fusion inhibitors, such as Roche Holding AG's Fuzeon, said Trevor Burt, Newsday,

Biotech Exhibiting a Quiet Strength  -  Jun 25, 2008
The shortage is mainly due to lackluster sales of its product Fuzeon, which was $17 million, versus our estimate of $28.5 million. istockAnalyst.com,

Zacks Analyst Interview Highlights: Celgene, Regeneron, Myriad ...  -  Jun 12, 2008
The shortage is mainly due to lackluster sales of its product Fuzeon, which was $17 million, versus our estimate of $28.5 million. FOXBusiness

Zacks Analyst Interview Highlights: Celgene, Regeneron, Myriad ...  -  Jun 26, 2008
The shortage is mainly due to lackluster sales of its product Fuzeon, which was $17 million, versus our estimate of $28.5 million. FOXBusiness

Trimeris to give shareholders most of its cash  -  May 9, 2008
Something like Thursday's announcement was expected from Trimeris, whose main product is an HIV treatment known as Fuzeon. Trimeris once employed 150 and Bizjournals.com,

Prospects shrink for Trimeris  -  May 16, 2008
What happens after that, analysts agree, depends on profits from the sale of its HIV/AIDS drug Fuzeon. The large, institutional investors that make up TMCnet

Examine The Fastest Growing Biotechnology Companies: Growth ...  -  May 12, 2008
Patents and proprietary rights 183 Strategic approach and positioning 183 Strengths 184 Collaboration with Roche 184 Fuzeon 185 Weaknesses 185 T-1249 on Earthtimes (press release),

Biotech Continues to Outperform  -  May 29, 2008
The shortage is mainly due to lackluster sales of its product Fuzeon, which was $17 million, versus our estimate of $28.5 million. istockAnalyst.com,

Zacks Analyst Interview Highlights: Celgene, Regeneron, Myriad ...  -  May 29, 2008
The shortage is mainly due to lackluster sales of its product Fuzeon, which was $17 million, versus our estimate of $28.5 million. PR-Inside.com (Pressemitteilung),

Company reports earnings of $0.10 per share for the first quarter ...  -  May 8, 2008
This decrease was primarily driven by lower worldwide FUZEON ® sales. Total revenue and collaboration income in the first quarter of 2007, including the Business Wire (press release),

Monday Options Outlook: XLE, YHOO, TGT, TRMS, BGP, STI, ECL, GES, PVH  -  May 19, 2008
...are unusually stretched in this biotech, whose recent dramatic historic includes patent infringement suit by Novartis (NVS) over its AIDS drug Fuzeon. Seeking Alpha,

Zacks Bull and Bear of the Day Highlights: Time Warner Telecom ...  -  May 15, 2008
The company registered a 34 percent year-over-year decline in Fuzeon sales for the first quarter of 2008. We attribute the decline to the withdrawal of the PR-Inside.com (Pressemitteilung),

Trimeris says sales of HIV drug Fuzeon fell 34 pct. in 1Q  -  Apr 16, 2008
AP 04.16.08, 5:15 PM ET Biotechnology company Trimeris Inc. said Wednesday that worldwide sales of its HIV treatment Fuzeon fell 34 percent during the first Forbes,

Trimeris Reports First Quarter 2008 FUZEON(R) Sales Results  -  Apr 16, 2008
Trimeris, Inc. (Nasdaq: TRMS) today announced worldwide net sales of FUZEON for the first quarter of 2008 were $42.7 million, down 34 percent from $64.3 Genetic Engineering News (press release),

Trimeris Reports First Quarter 2008 FUZEON ® Sales Results  -  Apr 16, 2008
Net sales of FUZEON in the US and Canada for the first quarter of 2008 were $17.0 million, down 42 percent from $29.3 million in the first quarter of 2007. Business Wire (press release),

Sales of Trimeris' HIV drug drop 34%  -  Apr 16, 2008
The one-third decline is well below the 9 percent yearly fall Trimeris saw for Fuzeon in the fourth quarter of 2007. Competing treatments, including those Bizjournals.com,

Rivals cut into sales of Trimeris' AIDS drug  -  Apr 18, 2008
Shares of Trimeris fell Thursday after the Morrisville company reported that first-quarter sales of its Fuzeon AIDS drug dropped 34 percent. News & Observer,

S&P Equity Research Downgrades Trimeris (TRMS) to Sell  -  Apr 17, 2008
S&P analyst, J. Loo, says, "TRMS posts Q1 fuzeon sales of $17M in the US and Canada, down 42% from a year ago and down 46% from Q4. StreetInsider.com (subscription),

Sales of Trimeris AIDS Drug Plunge in First Quarter  -  Apr 17, 2008
Morrisville, NC — Sales of the Trimeris AIDS drug Fuzeon plunged 34 percent in the first quarter, the biopharmaceutical firm reported Wednesday. WRAL.com,

Sell Trimeris to $5 Level  -  Apr 18, 2008
The company registered a 34 percent year-over-year decline in Fuzeon sales for the first quarter of 2008. We attribute the decline to the withdrawal of the Trading Markets (press release),

Roche Continues Solid Sales Growth in First Quarter of 2008 - Both ...  -  Apr 17, 2008
Sales of Fuzeon (enfuvirtide) declined sharply, in line with expectations, to 46 million francs (-38%), reflecting the availability of newer, PharmaLive.com (press release),

ALSO NOTED: Merck KGaA has money for deals; Alcon gets FDA OK for ...  -  Apr 17, 2008
Release > Sales of the Trimeris HIV drug Fuzeon plummeted during the first quarter to $42.7 million from $64.3 million during the first quarter of 2007. FiercePharma,

Trimeris to Release Fourth Quarter and Year End 2007 Financial ...  -  Mar 6, 2008
FUZEON, approved in the US, Canada and European Union, is the first in a new class of anti-HIV drugs called fusion inhibitors. For more information about Business Wire (press release),

AIDS drug maker likely seeking a buyer  -  Feb 11, 2008
Sales growth of Fuzeon fell to 7 percent last year, from a 20 percent growth rate two years ago, after the introduction of two new medicines that compete News & Observer,

Trimeris to add two investors to its board  -  Feb 11, 2008
Trimeris once was one of the Triangle's most promising young biotechnology companies, but its AIDS drug Fuzeon -- its only product -- fell short of high News & Observer,

Trimeris gives two board seats to HealthCor  -  Feb 9, 2008
But sales of its only drug, AIDS treatment Fuzeon, have been lower than expected thanks to the drug's high price and the unpleasantness of taking the Charlotte Business Journal,

Peptide pride  -  Mar 6, 2008
...an infection fighter from Cubist Pharmaceuticals Inc. of Lexington, and the anti-HIV drug Fuzeon from F. Hoffmann-LaRoche Ltd. and Trimeris Inc. Frost Worcester Telegram,

Brand Names/Synonyms:
Fuzeon is also known by the following brand names and/or synonymsEnvelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein;GP120; Transmembrane glycoprotein;GP41]; Fuzeon (Roche Pharmaceuticals)

Drug Category:
Fuzeon is categorized under the following by the FDA: Anti-HIV Agents

Dosage Forms:
Not Available

Absorption:
Not Available

Interactions:
Not Available

Chemical IUPAC Name:
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.